Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Chief Operating Officer | April 27, 2026 | April 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date April 27, 2026 · Filed April 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-04-27 | Direct | 400,000 |
Reported balance
After 2026-04-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-27 · Grant · Acquired 400,000 · Balance 400,000 F1: 100,000 vest on April 27, 2027 and 8,333 vest monthly for 36 months beginning on May 27, 2027 |
Filing footnotes · ownership attribution and instrument terms
F1: 100,000 vest on April 27, 2027 and 8,333 vest monthly for 36 months beginning on May 27, 2027
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2026 Filed Apr 28, 2026 22:13 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 400,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0002132312-26-000004 · ownership.xml · derivative · entry 1 Aggarwal Ajay · CIK 0002132312 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2036-04-27 F1 · derivative.exercise_date: 100,000 vest on April 27, 2027 and 8,333 vest monthly for 36 months beginning on May 27, 2027 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.